Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Operating Leases (2020 - 2025)

Revolution Medicines (RVMD) has 5 years of Operating Leases data on record, last reported at $121.4 million in Q1 2025.

  • For Q1 2025, Operating Leases changed N/A year-over-year to $121.4 million; the TTM value through Mar 2025 reached $121.4 million, changed N/A, while the annual FY2024 figure was $123.0 million, N/A changed from the prior year.
  • Operating Leases reached $121.4 million in Q1 2025 per RVMD's latest filing, down from $123.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $123.0 million in Q4 2024 and bottomed at $57.4 million in Q4 2022.
  • Average Operating Leases over 4 years is $80.0 million, with a median of $60.0 million recorded in 2021.
  • Peak YoY movement for Operating Leases: surged 108.4% in 2021, then decreased 4.94% in 2022.
  • A 4-year view of Operating Leases shows it stood at $60.4 million in 2021, then dropped by 4.94% to $57.4 million in 2022, then soared by 114.12% to $123.0 million in 2024, then fell by 1.31% to $121.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $121.4 million in Q1 2025, $123.0 million in Q4 2024, and $57.4 million in Q4 2022.